Hepatitis Drugs Market 2022 – Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Market Size & Forecast 2030

Page: 375 | Report Code: LS22310102 | Research Suite: Report (PDF) & Market Data (Excel)

Request Sample Pages to Get Table of Content

The global hepatitis drugs market is estimated to grow at a CAGR of 25.0% during the forecast period 2022-2030. 


Hepatitis is identified as one of the principal causes of mortality across the globe. Close to 0.8 million deaths are recorded every year due to complications arising from hepatitis type B, whereas hepatitis C is held responsible for approximately 0.5 million mortality cases every year.


Hepatitis is an inflammatory medical condition that affects the liver severely. The condition can also affect the digestive system and brain of the individual up to serious levels.  It can either lead to acute, semi-acute or chronic infection. The most common hepatitis is viral hepatitis which can be caused by any of the five hepatotropic viruses A, B, C, D, and E. However, there are three major types of hepatitis conditions known - HAV, HBV, and HCV. Apart from bacterial & viral infections, the condition can be caused by autoimmune diseases, heavy alcohol consumption, toxins, and certain prescription medications.


Currently, vaccines are available only for Hepatitis type A and Hepatitis type B viruses. However, research into the development of vaccines for Hepatitis type C is under development.



The rising incidences of different types of hepatitis cases across the world, the burgeoning demand for drugs to treat and manage hepatitis cases, the surging awareness among people, the growing geriatric population, the escalating healthcare expenditure, and investments in the development of drugs and therapy for hepatitis by public and private organizations and the growing number of new product launches and regulatory approvals of hepatitis drugs by authorities are the primary factors driving the growth of the global hepatitis drugs market.


Additionally, the emphasis of market players on research and development activities for gaining approval for various clinical trials for future HCV and HBV drugs to be commercially available in the market has been increasing rapidly. Alongside, the introduction of new therapies in the market such as that of interferon-free combination regimens and second generation DAAs which are expected to attain higher SVR and cause lesser side effects than currently are expected to bring about tremendous growth opportunities for the global hepatitis market in the forthcoming years.


Moreover, the increasing number of promotional activities and funding by market players and government associations to support the development of drug therapies & diagnosis and also for providing tailor-made solutions to patients is a major factor set to augment the growth of the market in the next few years.  Some of the major organizations involved include Centers for Disease Control and Prevention (CDC), American Liver Foundation, WHO, U.S. Department of Health and Human Services (HHS), Immunization Action Coalition, and Hepatitis Foundation International (HFI).


Furthermore, other factors such as the increasing number of collaborations and mergers & acquisitions among the major market players for offering novel solutions to treat hepatitis infections, the emerging trend of pediatric combination vaccines which aid in the protection against multiple causative agents and the growing launching of generic versions of existing brands are anticipated to further fuel the growth of the global hepatitis drugs market during the forecast period.


However, factors such as the high capital requirement for the manufacturing, development, and commercialization of drugs indicated for the treatment of hepatitis and the pro-longed development process and approval time of new pharmaceutical drugs are projected to restrict the market's growth up to some extent during the forecast period.



By Drug Class

·         Interferon Alphas

·         HIV NRTIs

·         Nucleotide Polymerase / NS5A Inhibitor Combinations

·         Hepatitis C Protease / NS5A Inhibitor Combinations

·         NS5A Inhibitors

·         Nucleotide Polymerase Inhibitors

·         Nucleoside Analogue Antivirals

·         Thrombopoiesis Stimulating Agents

By Disease Type

·         Hepatitis A

·         Hepatitis B

·         Hepatitis C

·         Others

By Route of Administration

·         Oral

·         Injection

By Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

By Region

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East and Africa


Based on disease type, the hepatitis C segment accounted for the largest market share of 82.0% in the global hepatitis drugs market in 2021. The segment is anticipated to retain its dominance in the market and witness the highest growth rate in the market during the forecast period.



The North American region held the most dominating position in the global hepatitis drugs market in 2021, followed by Europe. The region is estimated to further retain its dominance in the market over the forecast period. The growth of the market in the region can be attributed to the growing number of initiatives and measures taken up by the private organizations and governments to raise awareness and prevent hepatitis infections in the region, the escalating investments in the R&D to improve healthcare infrastructures in the region and the rising healthcare expenditure in the region. The U.S. is the major contributor to the growth of the market in the region.


The Asia Pacific region is projected to emerge as the fastest-growing regional market for hepatitis drugs globally during the forecast period due to factors such as the proliferating prevalence rate of hepatitis in the region's major economies and the burgeoning demand for generic drugs in the region. The major contributors to the region include India and China.


The Middle East and African region is also expected to hold a significant portion of the global hepatitis drugs market during the forecast period due to the rising popularity and usage of various HBV and HCV drugs in the region, especially in the parts of Africa.



·         Novartis AG

·         Dynavax Technologies Corporation

·         F. Hoffmann-La Roche Ltd.

·         Mitsubishi Tanabe Pharma Corporation

·         Bristol-Myers Squibb Company

·         LAURUS Labs

·         Gilead Sciences Inc.

·         Abbvie Inc.

·         Johnson & Johnson

·         Merck & Co. Inc.

·         GlaxoSmithKline plc

·         Vertex Pharmaceuticals Inc.

·         Zydus Cadila

·         Hetero Healthcare Limited

·         Cipla Inc.

·         Other Players

Buy Report

  • $1990
  • $3150